For UK MedTech companies
Your MedTech works. The right funding route determines whether it scales.
UK MedTech funding spans grant bodies, strategic investors and trade buyers, each demanding a different pitch and evidence base. Most companies approach the wrong route first, losing time they cannot recover.
Two minutes. Solva follows up with specific funding route options.
- Multiple unsuccessful funding rounds due to generic pitches
- Prolonged fundraising periods impacting product development timelines
- Missed opportunities with ideal investors who were not approached correctly
- Burnout of leadership teams due to continuous, unfocused fundraising efforts
- Diversion of key personnel from core R&D and commercial activities to fundraising
- Delayed market entry and reduced competitive advantage
- Increased burn rate and depletion of existing capital
- Lower valuations in subsequent funding rounds due to perceived instability
- Delayed patient access to innovative MedTech solutions
- Reduced ability to conduct comprehensive clinical trials for evidence generation
- Perception of instability or lack of commercial viability among potential partners and customers
- Difficulty in attracting future investment due to a history of failed funding rounds
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
MedTech funding in the UK has specific routes, Innovate UK, NIHR, strategic investors, and trade buyers. Each requires a different pitch and a different evidence base. Most companies approach the wrong investors with the wrong pitch.
What is the cost of leaving it unaddressed?
Around 50% of the MedTech industry expect to delay the introduction of their innovative medical products into the UK market (CPI Group, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.